It is of particular interest to note that in the treatment of schizophrenia, new therapeutic strategies consist in targeting both 5-HT1ARs and DA receptors by combining either 5-HT1ARs agonists with D2Rs antagonists (Newman-Tancredi, 2010) or 5-HT1A agonists with a D1R agonist and a D2R antagonist to prevent positive and negative symptoms of schizophrenia (Newman-Tancredi and Kleven, 2011). This evidence concerns the gene DRD1 and schizophrenia.